NEW YORK (GenomeWeb News) – Synthetic biology firm Intrexon reported after the close of the market Thursday that its second quarter revenues jumped more than 150 percent year over year as the firm trimmed its loss.

The Germantown, Md.-based firm, which went public in early August, brought in total revenues of $6.8 million for the three months ended June 30, up sharply from $2.7 million for the second quarter of 2012.

Its net loss was cut to $6.5 million, or $2.46 per share, from $16.5 million, or $3.99 per share.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: oral microbiomes of dogs and their owners, Plasmodium vivax population structure, and more.

The American Society of Human Genetics has issued a position statement on genetic testing of children.

The White House seeks to update how biotechnology products are regulated.

Team science leads some researchers to get lost in the shuffle, the Chronicle of Higher Education reports.